DigestRedComo funciona
Red
/
Empresas
En
No verificado

Endeavor BioMedicines

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

9 Comunicados de prensa

Ver todos los comunicados de prensa
03/11/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Endeavor BioMedicines Receives Priority Medicines (PRIME) Designation from the European Medicines Agency for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
Fuente
Endeavor BioMedicines
Editor
Business Wire
1.00
0
30/09/2025
Endeavor BioMedicines Announces Publication of Positive Data from Phase 2a Trial in The Lancet Respiratory Medicine Evaluating taladegib (ENV-101) in Individuals with Idiopathic Pulmonary Fibrosis
Fuente
Endeavor BioMedicines
Editor
Business Wire
1.00
0
10/09/2025
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Endeavor BioMedicines to Present Results from Phase 2a Trial of Taladegib (ENV-101) in an ALERT Session at European Respiratory Society (ERS) Congress 2025
Fuente
Endeavor BioMedicines
Editor
Business Wire
1.00
0
16/07/2025
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
Fuente
Endeavor BioMedicines
Editor
Business Wire
1.00
0
20/05/2025
Industria
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis
Fuente
Endeavor BioMedicines
Editor
Business Wire
1.00
0
01/05/2025
Eventos
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Endeavor BioMedicines Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Fuente
Endeavor BioMedicines
Editor
Business Wire
1.00
0
02/04/2025
Mercado laboral
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Endeavor BioMedicines Appoints Internationally Renowned ILD Expert Lisa Lancaster, M.D., as Chief Medical Officer
Fuente
Endeavor BioMedicines
Editor
Business Wire
1.00
0
20/11/2024
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Industria
First Patient Dosed in Endeavor BioMedicines’ Phase 2b WHISTLE-PF Trial Evaluating ENV-101 for the Treatment of Idiopathic Pulmonary Fibrosis
Fuente
Endeavor BioMedicines
Editor
Business Wire
1.00
0
12/09/2024
Endeavor BioMedicines Appoints Bill Bradford, M.D., Ph.D., to Board of Directors
Fuente
Endeavor BioMedicines
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0